What does the evidence say about Chlorogenic Acid Cardiometabolic Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Chlorogenic Acid Cardiometabolic Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Pre-obesity is a condition that predisposes to the risk of developing obesity, cardiovascular diseases (CVD), and diabetes. [Terzo S (2023); evidence level 2] - After six months of treatment Altilix® significantly reduced body weight, glycemic, and lipid parameters (total cholesterol, triglycerides, LDL-cholesterol) and improved hepatic functionality, CIMT, and FMD. [Terzo S (2023); evidence level 2] - In conclusion, these results confirm that Altilix® supplementation has a significant effect on cardiometabolic parameters not only in obese subjects but also in pre-obesity subjects. [Terzo S (2023); evidence level 2] - Our previous study demonstrated that a Cynara cardunculus (L.) based nutraceutical named Altilix® (Bionap, Italy), containing chlorogenic acid and luteolin extracts, was able to improve several hepatic and cardio-metabolic parameters. [Terzo S (2023); evidence level 2] - It also significantly improved thermotolerance and resistance to oxidative stress in C . [Todorova MN (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.